We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

20 hedge funds and large institutions have $878K invested in Galmed Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.05% → 0.05% (-0.01%)

9% less funds holding

Funds holding: 22 → 20 (-2)

28% less capital invested

Capital invested by funds: $1.21M → $878K (-$336K)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
20
Holders Change
-2
Holders Change %
-9.09%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$24.4K
2
VF
Virtu Financial
New York
+$18.9K
3
Morgan Stanley
Morgan Stanley
New York
+$14.1K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$7.84K
5
AF
Allworth Financial
California
+$107

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$234K
2
Millennium Management
Millennium Management
New York
-$10.5K
3
UBS Group
UBS Group
Switzerland
-$10.2K
4
Jane Street
Jane Street
New York
-$8.37K
5
SG
StoneX Group
New York
-$5.28K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$575K -$234K -2,177 -23%
Morgan Stanley
2
Morgan Stanley
New York
$87.1K +$14.1K +131 +13%
RJA
3
Raymond James & Associates
Florida
$58.9K – – –
Millennium Management
4
Millennium Management
New York
$56K -$10.5K -98 -12%
Citadel Advisors
5
Citadel Advisors
Florida
$17.4K +$24.4K +227 New
VF
6
Virtu Financial
New York
$13K +$18.9K +176 New
WWM
7
Western Wealth Management
Colorado
$12.6K – – –
Cambridge Investment Research Advisors
8
Cambridge Investment Research Advisors
Iowa
$12K – – –
RJFSA
9
Raymond James Financial Services Advisors
Florida
$11.9K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$11.6K – – –
BAM
11
Belpointe Asset Management
Nevada
$5.99K – – –
BNP Paribas Financial Markets
12
BNP Paribas Financial Markets
France
$5.85K +$7.84K +73 +2,433%
Jane Street
13
Jane Street
New York
$5.63K -$8.37K -78 -52%
UBS Group
14
UBS Group
Switzerland
$1.83K -$10.2K -95 -80%
Wells Fargo
15
Wells Fargo
California
$1.3K – – –
FDCDDQ
16
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.07K – – –
TFGT
17
TS Financial Group (TSFG)
Illinois
$1K – – –
BCM
18
Bourgeon Capital Management
Connecticut
$214 – – –
AF
19
Allworth Financial
California
$107 +$107 +1 New
EWP
20
Elevation Wealth Partners
California
$43 +$107 +1 New
Northwestern Mutual Wealth Management
21
Northwestern Mutual Wealth Management
Wisconsin
$4 – – –
SG
22
StoneX Group
New York
– -$5.28K -59 Closed
GSC
23
Ground Swell Capital
South Carolina
– -$5.18K -58 Closed
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
– -$5K -56 Closed
AWM
25
Accurate Wealth Management
Florida
– -$1K -6 Closed
1
2

GLMD Hedge Fund Activity: Q1 2023 in Review

20 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2023, worth a combined $878K — down 28% from $1.21M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of GLMD and 4 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $24.4K. The largest seller was BVF Inc, cutting an estimated $234K.

  • 20 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2023, down from 22 in Q4 2022.
  • Funds reported $878K of Galmed Pharmaceuticals stock for Q1 2023, down 28% quarter-over-quarter.
  • 4 funds opened new Galmed Pharmaceuticals positions in Q1 2023 and 6 closed out, a net change of -2 holders.
  • The largest Galmed Pharmaceuticals buyer in Q1 2023 was Citadel Advisors, an estimated $24.4K added.
  • The largest Galmed Pharmaceuticals seller in Q1 2023 was BVF Inc, an estimated $234K sold.

Based on aggregated 13F filings for Q1 2023.